Literature DB >> 3323254

Screening test for rheumatic diseases: a combined enzyme immunoassay of rheumatoid factors and antibodies to DNA and extractable nuclear antigens.

P Kurki1, M Gripenberg, P Partanen, T Helve.   

Abstract

Three hundred and one sera from patients with rheumatic and other diseases were investigated using a simple enzyme immunoassay for screening of rheumatoid factors and antinuclear antibodies. The assay had a sensitivity of 77% for systemic lupus erythematosus, 90% for the primary sicca syndrome, and 89% for rheumatoid arthritis. Only 13% of sera from patients with chronic non-rheumatic diseases were positive. The test was further evaluated in a group of patients with suspected rheumatic disease who were followed up for six to 12 months. The test was positive in 16 of 17 sera from patients with connective tissue diseases but in only seven of 36 sera (19%) from patients with non-inflammatory joint diseases. None of the four patients with reactive arthritis was positive by this test. The sensitivity of the assay was comparable with that of the agglutination and immunofluorescence tests for rheumatoid factors and antinuclear factors. For the screening of rheumatoid factor and antinuclear antibodies this kind of test panel offers a simple alternative to the conventional tests for small clinical laboratories and for those in which the autoantibody tests could be automated, as the assay can be performed in one working day and only one dilution of serum is needed to obtain a quantitative result.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3323254      PMCID: PMC1141287          DOI: 10.1136/jcp.40.12.1475

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  26 in total

1.  1958 Revision of diagnostic criteria for rheumatoid arthritis.

Authors:  M W ROPES; G A BENNETT; S COBB; R JACOX; R A JESSAR
Journal:  Bull Rheum Dis       Date:  1958-12

2.  Evaluation of the simultaneous estimation of anti-dsDNA and anti-ssDNA antibodies for clinical purposes.

Authors:  A Lange
Journal:  Clin Exp Immunol       Date:  1978-03       Impact factor: 4.330

3.  A solid phase enzyme-linked immunosurbent assay (ELISA) for the demonstration of antibodies against denatured, single-stranded DNA in patient sera.

Authors:  M Gripenberg; E Linder; P Kurki; E Engvall
Journal:  Scand J Immunol       Date:  1978       Impact factor: 3.487

4.  The clinical significance of titered antinuclear antibodies.

Authors:  R F Ritchie
Journal:  Arthritis Rheum       Date:  1967-12

5.  Identification of the immunogenically active components of the Sm and RNP antigens.

Authors:  P J White; W D Gardner; S O Hoch
Journal:  Proc Natl Acad Sci U S A       Date:  1981-01       Impact factor: 11.205

6.  A simple enzyme immunoassay for the demonstration of rheumatoid factor.

Authors:  M Gripenberg; F Wafin; H Isomäki; E Linder
Journal:  J Immunol Methods       Date:  1979       Impact factor: 2.303

7.  Purification and characterization of a nuclear SS-B antigen.

Authors:  A M Teppo; M Gripenberg; P Kurki; K Baklien; T Helve; O Wegelius
Journal:  Scand J Immunol       Date:  1982-01       Impact factor: 3.487

8.  Anti-ENA antibody in serum determined by ELISA-technique. Description of method and recommended procedure.

Authors:  J Struckmann; R Manthorpe; G Bendixen
Journal:  Allergy       Date:  1981-08       Impact factor: 13.146

9.  Serological findings in patients with "ANA-negative" systemic lupus erythematosus.

Authors:  P J Maddison; T T Provost; M Reichlin
Journal:  Medicine (Baltimore)       Date:  1981-03       Impact factor: 1.889

Review 10.  Rheumatoid factor: its nature, specificity, and production in rheumatoid arthritis.

Authors:  P M Johnson; W P Faulk
Journal:  Clin Immunol Immunopathol       Date:  1976-11
View more
  1 in total

1.  Anti-idiotype antibodies in immune regulation of anca associated vasculitis.

Authors:  Vandana D Pradhan; Kanjaksha Ghosh
Journal:  Indian J Dermatol       Date:  2009-07       Impact factor: 1.494

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.